Donate For Public and Patients Store Search

S010 - Skin of Color

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Diagnose various skin conditions commonly seen in patients with skin of color
  • Choose optimal treatments for skin conditions commonly seen in patients with skin of color

Description

This session will provide attendees with insight into skin conditions more commonly seen in patients with skin of color and provide ways to better diagnose and manage these conditions. Disorders of pigmentation, CCCA, keloids and hidradenitis suppurativa will be covered

Disclosures

  • Glass, Donald A. II, MD, PhD: no financial relationships exist with commercial interests.
  • Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); Dermavant Sciences – C(Fees), I(Grants/Research Funding); Dermira – I(Grants/Research Funding); EMD Serono – C(H); Genzyme Corporation – C(H), I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Leo Pharma Inc – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Rheos Medicines – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); TeVido Biodevices, LLC – A(SO), I(Grants/Research Funding), SH(ST); Third Rock Ventures – A(H); Villaris Therapeutics, Inc – F(ST), I(Grants/Research Funding);
  • McMichael, Amy J., MD: Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding); Allergan, Inc. – C(H), I(OB); Anacor Pharmaceuticals, Inc. – A(H); Cassiopea S.p.A. – I(Grants/Research Funding); Concert Pharmaceuticals – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(OB); Incyte Corporation – C(H), I(Grants/Research Funding); Informa – O(OB); JAMA – O(NC); Johnson & Johnson Consumer Products Company – C(H); NAAF – A(NC); North American Hair Research Society – B(NC); Procter & Gamble Company – C(H), I(OB); Samumed, LLC – C(H); UpToDate, Inc – Speaker/Faculty Education(H);
  • Pandya, Amit G., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Clarify Medical Inc. – B(ST); Incyte Corporation – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding);
Schedule
Friday, March 1
1:00 PM
Dr. McMichael / Approach to the patient with CCCA
1:30 PM
Dr. Hamzavi / Improving the lives of patients with hidradenitis suppurativa
2:00 PM
Dr. Glass / Management of keloids: State of the art
2:30 PM
Dr. McMichael, Dr. Hamzavi, and Dr. Glass / Questions and answers
2:45 PM
Dr. Pandya / Unmasking facial hyperpigmentation
3:15 PM
Dr. Harris / What's new in vitiligo
3:45 PM
Dr. Pandya and Dr. Harris / Questions and answers
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 204A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
Speakers
  • Amy J. McMichael, MD, FAAD
  • Donald A. Glass II, MD, PhD, FAAD - Handout
  • Iltefat H. Hamzavi, MD, FAAD - Handout
  • John Harris, MD, PhD, FAAD